Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Gross Profit (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Gross Profit for 15 consecutive years, with $56.7 million as the latest value for Q4 2025.

  • Quarterly Gross Profit rose 41.77% to $56.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $253.5 million through Dec 2025, up 62.46% year-over-year, with the annual reading at $253.5 million for FY2025, 62.46% up from the prior year.
  • Gross Profit hit $56.7 million in Q4 2025 for Ligand Pharmaceuticals, down from $111.7 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $111.7 million in Q3 2025 to a low of $24.7 million in Q2 2023.
  • Historically, Gross Profit has averaged $42.7 million across 5 years, with a median of $40.1 million in 2023.
  • Biggest five-year swings in Gross Profit: crashed 35.24% in 2022 and later surged 126.2% in 2025.
  • Year by year, Gross Profit stood at $44.4 million in 2021, then plummeted by 35.24% to $28.8 million in 2022, then decreased by 8.02% to $26.5 million in 2023, then soared by 51.08% to $40.0 million in 2024, then soared by 41.77% to $56.7 million in 2025.
  • Business Quant data shows Gross Profit for LGNDZ at $56.7 million in Q4 2025, $111.7 million in Q3 2025, and $44.7 million in Q2 2025.